ERBB2 and glioblastoma: Various GBM antigens have been found as a potential target for CAR T cells, from which epidermal growth factor receptor variant III (EGFRvIII), human epidermal growth factor receptor 2 (HER2), and interleukin-13 receptor alpha 2 (IL-13Rα2) have been clinically verified as effective targets of CAR T cell therapy for GBM [203].